Albumin binding comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2026-03-27. Where a claim depends on a specific study, the study is described rather than over-claimed.
Once in circulation, the peptide binds the growth hormone-releasing hormone receptor displayed on pituitary somatotroph cells. Receptor activation couples to Gs proteins, elevates intracellular cyclic AMP, and drives protein kinase A signaling inside the cell. That cascade increases discharge of growth hormone into the bloodstream. The analog therefore operates through a receptor pathway that already exists for the body's own releasing hormone, rather than through an engineered artificial target.
Clearance profiles diverge sharply between the two versions. The albumin-binding molecule stays in plasma for several days, whereas the unmodified analog is largely gone within about half an hour in reported work. Cleavage by dipeptidyl peptidase IV is a major contributor to the short life of the unmodified sequence. These gaps mean the two versions cannot be substituted for each other in study design or in reading results side by side.
CJC-1295 is a synthetic peptide designed to mimic growth hormone-releasing hormone (GHRH), the endogenous signal that prompts the pituitary gland to release growth hormone. The compound is a modified fragment of the natural hormone, spanning the first twenty-nine amino acids of GHRH with several substitutions that slow enzymatic breakdown. Two variants circulate in research settings: one carrying a drug affinity complex (DAC) and one without it. The DAC-free form is frequently labelled Mod GRF(1-29) in catalogs and discussion forums.
The peptide binds GHRH receptors on somatotroph cells within the anterior pituitary, triggering a signalling cascade that increases growth hormone secretion. Its improved resistance to dipeptidyl peptidase IV degradation distinguishes it from the parent hormone. In the DAC-bearing version, a maleimide group reacts with a cysteine residue on serum albumin, forming a covalent bond that keeps the peptide in circulation far longer. That albumin attachment is the central design feature separating the two research variants.
Pharmacokinetic behaviour differs sharply between the two forms. The DAC-bearing peptide shows an extended circulation time measured in days, whereas the version without the complex is cleared within roughly half an hour. This gap shapes how researchers design dosing schedules in animal models. Whether the prolonged presence of the DAC form produces effects meaningfully different from the short-acting variant remains an open question, since comparative human data are scarce.
| Property | Value | Notes |
|---|---|---|
| Primary target | GHRH receptor | Present on pituitary somatotroph cells |
| Signal pathway | Gs, cyclic AMP, protein kinase A | Sequence follows receptor activation |
| Main measured effect | Growth hormone release | Insulin-like growth factor 1 shifts indirectly |
| Half-life, binding form | Several days | Extended through serum albumin association |
| Half-life, unmodified form | About 30 minutes | Limited mainly by enzymatic cleavage |
CJC-1295 is a synthetic peptide designed as a long-acting analogue of growth hormone-releasing hormone (GHRH). Its structure derives from the first 29 amino acids of native GHRH, a fragment often called GRF(1-29). Four substitutions were introduced to slow enzymatic breakdown and extend activity relative to the natural sequence. The compound was developed by ConjuChem as part of a broader effort to improve the pharmacokinetic profile of peptide hormones. It is studied in laboratory and clinical research settings rather than appearing as a naturally occurring substance.
Two related forms circulate in technical discussion under the same family name. The original version carries a drug affinity complex (DAC) that binds covalently to serum albumin after administration, and this linkage substantially extends circulation time. A second form, frequently written as modified GRF(1-29) or CJC-1295 without DAC, lacks that linker and clears much faster. The naming is a frequent source of confusion because the shorthand CJC-1295 can refer to either form depending on the source. Reports sometimes fail to specify which variant was studied.
The peptide backbone corresponds to GRF(1-29), the first 29 residues of native growth hormone-releasing hormone, which retains most of the receptor-activating activity of the full-length molecule. Four substitutions distinguish the analog from the natural sequence: D-alanine at position 2, glutamine at position 8, alanine at position 15, and leucine at position 27. These changes slow cleavage by dipeptidyl peptidase IV, the enzyme that degrades native hormone in plasma within minutes. The outcome is improved enzymatic stability combined with a still brief residence time when no additional modification is present.
Naming in this area is inconsistent, and readers should treat product labels with care. In much of the literature and in vendor catalogs, the unqualified term refers to the albumin-binding version, while the version lacking the DAC group appears as modified GRF(1-29), mod GRF(1-29), or the same name with a without-DAC qualifier. Because one abbreviation has been applied to both materials, the only reliable way to identify a sample is to check the stated sequence and the presence of the linker.
CJC-1295 is a synthetic peptide belonging to the growth hormone-releasing hormone analog family. It comprises twenty-nine amino acid residues derived from the N-terminal region of natural GHRH. The molecule incorporates several non-natural substitutions that increase resistance to enzymatic degradation. These modifications extend its activity compared with the native hormone fragment. Researchers use it to study pituitary growth hormone secretion in laboratory and clinical settings. This compound is distinct from native GHRH in its stability profile.
Two principal forms appear in the literature and in research supply. One carries a drug affinity complex, a maleimide-based group that forms a covalent bond with circulating albumin. This linkage slows clearance and produces a long-lasting elevation of peptide levels. The other form lacks that group and is often labeled MOD GRF(1-29). It has a much shorter circulation time. Both variants retain the same core receptor-binding sequence. Reported half-lives differ substantially between the two.
At the pituitary, the peptide binds the growth hormone-releasing hormone receptor on somatotroph cells. Receptor activation raises intracellular cyclic AMP and triggers release of stored growth hormone. Somatostatin and other hypothalamic signals modulate this response. Negative feedback from insulin-like growth factor 1 also influences output. The same regulatory architecture operates with the native hormone. Whether the synthetic analog alters feedback dynamics over repeated exposure remains an open question. Most published receptor work uses cell models rather than intact human systems.
CJC-1295 is a synthetic peptide modeled on growth hormone-releasing hormone, the hypothalamic signal that prompts the pituitary to release growth hormone. Its sequence corresponds to the first twenty-nine residues of human GHRH, with four substitutions that slow enzymatic breakdown. Early descriptions placed the compound in research on growth hormone deficiency and related conditions, and later literature groups it with the long-acting GHRH analogs. The name appears in both laboratory and popular fitness writing, where it sometimes labels chemically different peptides.
Two related peptides circulate under the CJC-1295 label, and they differ mainly in how long they persist in circulation. The version carrying a drug affinity complex includes a maleimidopropionic acid linker that forms a covalent bond with serum albumin. The other version, usually written as modified GRF(1-29) or tetrasubstituted GRF(1-29), lacks that linker and is cleared quickly. Mixing the two produces inconsistent readings of published half-life values, because the linker rather than the receptor-facing sequence drives most of the difference.
The core sequence keeps the receptor-binding region of GHRH while replacing four positions that are vulnerable to dipeptidyl peptidase-4 and other proteases. Substitutions at positions 2, 8, 15, and 27 raise metabolic stability relative to the natural hormone. The N-terminal residues remain essential for activity, so changes there generally lower potency. Molecular weight sits near 3368 daltons for the tetrasubstituted analog without the linker, while the albumin-binding form is heavier because of the added maleimide group.
=== Heptapeptide backbone synthesis === The heptapeptide backbone of teicoplanin is assembled by the nonribosomal peptide synthetases (NRPSs) TeiA, TeiB, TeiC and TeiD. Together these comprise seven modules, each containing a number of domains, with each module responsible for the incorporation of a single amino acid. Modules 1, 4, and 5 activate L-4-Hpg as the aminoacyl-AMP, modules 2 and 6 activate L-Tyr, and modules 3 and 7 activate L-3,5-Dpg. The activated amino acids are covalently bound to the NRPS as thioesters by a phosphopantetheine cofactor, which is attached to the peptidyl carrier protein (PCP) domain. The enzyme bound amino acids are then joined by amide bonds by the action of the condensation (C) domain. The heptapetide of teicoplanin contains 4 D-amino acids, formed by epimerization of the activated L-amino acids. Modules 2, 4 and 5 each contain an epimerization (E) domain which catalyzes this change. Module 1 does not contain an E domain, and epimerization is proposed to be catalysed by the C domain. In all, six of the seven total amino acids of the teicoplanin backbone are composed of nonproteinogenic or modified amino acids. Eleven enzymes are coordinatively induced to produce these six required residues. Teicoplanin contains two chlorinated positions, 2 (3-Cl-Tyr) and 6 (3-Cl-β-Hty). The halogenase Tei8* has been acts to catalyze the halogenation of both tyrosine residues.
== Applications of machine learning in peptide prediction == Machine learning and deep learning architectures are extensively utilized to classify, screen, and design peptides based on sequence- and structure-derived data. These computational approaches are particularly valuable when experimental screening is cost-prohibitive, time-consuming, or difficult to scale. A standard workflow typically involves dataset curation, the transformation of peptide sequences or structures into numerical features, model optimization, and rigorous performance validation. Commonly used representations include amino acid composition, physicochemical descriptors, substitution matrices, and learned embeddings derived from protein or peptide language models. These methodologies have been successfully applied across various functional classes, such as antimicrobial peptides, cell-penetrating peptides, and anticancer agents. Current challenges in the field include addressing dataset biases, establishing consistent benchmarking protocols, and improving the interpretability of complex "black-box" models.
== History == Viscofan was founded in 1975, which is also when it began producing and selling its products. In 1988, Viscofan acquired the food group IAN (Industrias Alimentarias de Navarra), aiming to improve its presence in the Spanish market. Viscofan continued its international expansion by acquiring the German company Naturin GmbH & Co. in 1990 and opening new commercial offices overseas. Additional acquisitions included Gamex in the Czech Republic (1995), Trificel in São Paulo, Brazil (1995), Koteksprodukt AD in Serbia (2005), and the assets of Sweden's AB Tripasin (2005). In 2006, Viscofan broadened its footprint in the Americas by acquiring the U.S. and Mexican assets of Teepak. In 2008, Viscofan expanded its cogeneration plant in Spain. That same year, the company launched Viscofan Bioengineering, a business unit that merges bioscience and engineering to develop collagen-based products intended for tissue repair. The Bioengineering unit is located in Weinheim (Germany), where Viscofan also maintains a production site for collagen casings and an additional cleanroom facility for manufacturing medical-grade collagen materials. In 2009, Viscofan established Viscofan Technology (Suzhou) Co. Ltd. in China. The following year, it opened a converting plant in the country. In 2012, the company created Viscofan Uruguay S.A., followed by the opening of a collagen extrusion plant in China in 2013 and another extrusion facility in Uruguay in 2014. In 2015, Viscofan sold the IAN Group to focus on its casings business.
Sources: en.wikipedia.org
=== Collapse of the June ceasefire (July) === The ceasefire collapsed on 8 July 2026, after a brief period of reduced tension under a 14-point memorandum of understanding (MoU) signed on 14 June 2026. Trump declared the agreement "over" after Iran attacked three commercial vessels passing through the Strait of Hormuz. The United States Central Command retaliated by launching airstrikes against 80 targets throughout Iran, including Darkhovin Nuclear Power Plant. Following that, the Islamic Revolutionary Guard Corps carried out 85 counterattacks against US and allied military installations throughout the region, including those in Bahrain and Kuwait. Three US service members—1st Lt. Tyler James Feehan, Pvt. Isabella Gonzales, and Sgt. Angel S. Rampersad—were killed in one of those attacks on Muwaffaq Salti Air Base in Jordan that housed US personnel. The US then reinstated its naval blockade of Iranian ports and withdrew its temporary sanctions waivers. Global oil prices surged above $100 per barrel after the Houthis declared a naval blockade against Saudi Arabian shipping.
==== Rodent research ==== A study on the fossil record of Asian rodents spanning the last 55 million years, providing evidence of impact of tectonic and climatic changes on ecomorphological diversity of Asian rodent assemblages throughouth their evolutionary history, is published by Peng & Hopkins (2026). Pfaff, Ruf & Le Maître (2026) determine the locomotory behavior of extinct members of Eusciurida on the basis of the study of middle and inner ear of extant and extinct rodents, interpreting early rodents and sciurids as fossorial, with adaptations to arboreal lifestyle evolving in later taxa. Review of research on systematics of fossil dormice from Mediterranean islands from the preceding years is published by Fox & Hennekam (2026). Wei et al. (2026) reconstruct the evolutionary history of marmots on the basis of paleontological and molecular data. Murchie et al. (2026) report evidence of preservation of ancient environmental DNA of diverse Quaternary organisms from eastern Beringia in the Pleistocene and Holocene ground squirrel coprolites from Yukon (Canada), including evidence of previously unrecognized genetic diversity of Arctic members of the genus Urocitellus. Li, Bi & Li (2026) present the first virtual endocasts of Paleogene ctenodactyloids Exmus mini and Bounomys ulantatalensis. The first fossil material of Hystrix subcristata from Taiwan is reported from the Pleistocene Chiting Formation by Halaçlar & Lin (2026). Buldrini et al. (2026) describe fossil material of Phugatherium sp.
Malolactic conversion (also known as malolactic fermentation or MLF) is a process in winemaking in which tart-tasting malic acid, naturally present in grape must, is converted to softer-tasting lactic acid. Malolactic fermentation is most often performed as a secondary fermentation shortly after the end of the primary fermentation, but can sometimes run concurrently with it. The process is standard for most red wine production and common for some white grape varieties such as Chardonnay, where it can impart a "buttery" flavor from diacetyl, a byproduct of the reaction. The fermentation reaction is undertaken by the family of lactic acid bacteria (LAB); Oenococcus oeni, and various species of Lactobacillus and Pediococcus. Chemically, malolactic fermentation is a decarboxylation, which means carbon dioxide is liberated in the process. The primary function of all these bacteria is to convert L-malic acid, one of the two major grape acids found in wine, to another type of acid, L+ lactic acid. This can occur naturally. However, in commercial winemaking, malolactic conversion typically is initiated by an inoculation of desirable bacteria, usually O. oeni. This prevents undesirable bacterial strains from producing "off" flavors. Conversely, commercial winemakers actively prevent malolactic conversion when it is not desired, such as with fruity and floral white grape varieties such as Riesling and Gewürztraminer, to maintain a more tart or acidic profile in the finished wine. Malolactic fermentation tends to create a rounder, fuller mouthfeel.
Sources: en.wikipedia.org
In industry, a similar reaction is carried out at high pressure and temperature in the presence of quaternary ammonium or phosphonium salts as a catalyst. Reaction of ethylene oxide with formaldehyde at 80–150 °C in the presence of a catalyst leads to the formation of 1,3-dioxolane:
Lewis Namier (27 June 1888 – 19 August 1960), British historian of Polish-Jewish ancestry; descendant of Rabbi Elijah ben Solomon Zalman,(Hebrew: ר' אליהו בן שלמה זלמן) known as the Vilna Gaon; author of over twenty scholarly texts and authoritative monographs on sociopolitical typology and geopolitical analysis; held positions with Propaganda Department (1915–17), the Department of Information (1917–18) and with Political Intelligence Department of Foreign Office (1918–20); following defeat of Germany in World War One, Namier joined British delegation at Versailles Peace Conference of 1919; later Namier, who was a long-time Zionist, worked as political secretary for the Jewish Agency in Palestine (1929–31) and was close friend and associate of Chaim Weizmann; active in Zionist groups, lobbying British government to allow creation of Jewish Fighting Force in Mandate of Palestine and from 1933 was engaged in efforts on behalf of Jewish refugees from Germany. Namier used prosopography or collective biography of every Member of Parliament (MP) and peer who sat in the British Parliament in the latter 18th century to reveal that local interests, not national ones, often determined how parliamentarians voted. As former patient of Sigmund Freud, Namier was a believer in psychohistory. Saul Newman, anarchist scholar and activist,(born 22 March 1972) is a British political theorist who writes on post-anarchism. He is professor of political theory at Goldsmiths College, University of London.
==== About Huntleigh Nesbit Evans (HNE) ==== In 1969, the Flowtron Aire Ltd, the predecessor of Huntleigh Healthcare, was founded in Luton in 1975 that of the Huntleigh Group Ltd. In 1985 the company's IPO took place as a Huntleigh Technology PLC at the London Stock Exchange. In 1993 Huntleigh took over the Nesbit Evans Group and operated as HNE HUNTLEIGH NESBIT EVANS.
The vast majority of reported cases of foodborne illness occur as individual or sporadic cases. The origin of most sporadic cases is undetermined. In the United States, where people eat outside the home frequently, 58% of cases originate from commercial food facilities (2004 FoodNet data). An outbreak is defined as occurring when two or more people experience similar illness after consuming food from a common source. Often, a combination of events contributes to an outbreak, for example, food might be left at room temperature for many hours, allowing bacteria to multiply which is compounded by inadequate cooking which results in a failure to kill the dangerously elevated bacterial levels. Outbreaks are usually identified when those affected know each other. Outbreaks can also be identified by public health staff when there are unexpected increases in laboratory results for certain strains of bacteria. Outbreak detection and investigation in the United States is primarily handled by local health jurisdictions and is inconsistent from district to district. It is estimated that 1–2% of outbreaks are detected. When an outbreak is suspected, investigators conduct an epidemiologic assessment, laboratory analysis, and environmental assessment simultaneously. Investigators construct an epidemic curve, a histogram of cases over time, to characterize transmission patterns and narrow the exposure window. Case-control studies are commonly used, comparing foods eaten by ill individuals against those eaten by healthy controls to identify statistically significant exposures.
Sources: en.wikipedia.org
It acts on the growth hormone-releasing hormone receptor found on pituitary somatotroph cells. Activation of that receptor triggers growth hormone release through a cyclic AMP dependent pathway.
It links the peptide to serum albumin after administration, which delays removal from circulation. Reported half-life shifts from roughly half an hour to several days as a result.
Most published work tracks serum growth hormone and insulin-like growth factor 1 over time. Sampling schedules and assay methods vary enough that figures are not directly comparable across reports.
The synthetic peptide keeps the receptor-binding region of GHRH but carries substitutions that resist enzymatic cleavage. In the DAC version, an added group also anchors the molecule to albumin, extending its presence in the bloodstream.